日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Physiologically-Based Pharmacokinetic Model-Informed Labeling for Cariprazine Drug Interactions With CYP3A Inhibitors

基于生理药代动力学模型的卡利拉嗪与CYP3A抑制剂药物相互作用的标签标注

Riad, Md Mahbubul Huq; Marroum, Patrick; Shebley, Mohamad; Xiong, Hao

Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS-CoV-2 neutralizing monoclonal antibody ABBV-47D11 in patients with COVID-19

针对COVID-19患者的SARS-CoV-2中和单克隆抗体ABBV-47D11的安全性、药代动力学和抗病毒活性的I期研究

Shebley, Mohamad; Wang, Stanley; Ali, Izna; Krishnan, Preethi; Tripathi, Rakesh; Reardon, Joseph M; Cafardi, John; Rahav, Galia; Caraco, Yoseph; Slim, Jihad; Al Akhrass, Fadi; Yu, Mengjia; Hu, Yiran; Ferreira, Rosa De Abreu; Alami, Negar N

Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids

艾拉戈利克斯联合低剂量雌二醇/醋酸炔诺酮治疗子宫肌瘤女性患者的群体药代动力学

Beck, Denise; Winzenborg, Insa; Liu, Mohan; Degner, Jacob; Mostafa, Nael M; Noertersheuser, Peter; Shebley, Mohamad

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women

依拉戈利对健康绝经前女性体内奥美拉唑及其代谢物的药代动力学的影响

Ahmed Nader, Nael M Mostafa, Elaine Kim, Mohamad Shebley

Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure

基于生理的药代动力学建模和模拟,可为溶出度指标和释放速率对依拉戈利暴露的临床意义提供信息。

Mukherjee, Dwaipayan; Chiney, Manoj S; Shao, Xi; Ju, Tzuchi R; Shebley, Mohamad; Marroum, Patrick

A Personalized Medicine Approach Using Clinical Utility Index and Exposure-Response Modeling Informed by Patient Preferences Data

基于患者偏好数据的临床效用指数和暴露-反应模型的个性化医疗方法

Winzenborg, Insa; Soliman, Ahmed M; Shebley, Mohamad

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis

利用elagolix治疗子宫内膜异位症女性的3期临床试验数据验证钙稳态定量系统药理学模型

Stodtmann, Sven; Nader, Ahmed; Polepally, Akshanth R; Suleiman, Ahmed A; Winzenborg, Insa; Noertersheuser, Peter; Ng, Juki; Mostafa, Nael M; Shebley, Mohamad

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis

Elagolix的临床药理学:一种用于治疗子宫内膜异位症的口服促性腺激素释放激素受体拮抗剂

Shebley, Mohamad; Polepally, Akshanth R; Nader, Ahmed; Ng, Juki W; Winzenborg, Insa; Klein, Cheri E; Noertersheuser, Peter; Gibbs, Megan A; Mostafa, Nael M

Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse

利用临床药理学库加速儿科肿瘤药物研发

Shebley, Mohamad; Menon, Rajeev M; Gibbs, John P; Dave, Nimita; Kim, Su Y; Marroum, Patrick J

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective

基于生理的药代动力学模型验证和监管申报报告程序:联盟视角

Shebley, Mohamad; Sandhu, Punam; Emami Riedmaier, Arian; Jamei, Masoud; Narayanan, Rangaraj; Patel, Aarti; Peters, Sheila Annie; Reddy, Venkatesh Pilla; Zheng, Ming; de Zwart, Loeckie; Beneton, Maud; Bouzom, Francois; Chen, Jun; Chen, Yuan; Cleary, Yumi; Collins, Christiane; Dickinson, Gemma L; Djebli, Nassim; Einolf, Heidi J; Gardner, Iain; Huth, Felix; Kazmi, Faraz; Khalil, Feras; Lin, Jing; Odinecs, Aleksandrs; Patel, Chirag; Rong, Haojing; Schuck, Edgar; Sharma, Pradeep; Wu, Shu-Pei; Xu, Yang; Yamazaki, Shinji; Yoshida, Kenta; Rowland, Malcolm